Business
INVO Bioscience Reports Second Quarter 2021 Financial and Operating Results and Provides Business Update
Company to Host Conference Call Today at 4:30pm ET (Details Below) SARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Company to Host Conference Call Today at 4:30pm ET (Details Below)\n\n\nSARASOTA, Fla., Aug. 16, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world's only in vivo culture system, today announced financial and operating results for the second quarter ended June 30, 2021 and provides a business update.\n\n \n \n \n \n \n \n\n \nRecent Operational Highlights\nOfficially opened the first U.S.-based INVO Center, located in Birmingham, Alabama in partnership with reproductive specialists Dr. Nicholas Cataldo, MD, MPH, Dr. Karen R. Hammond, DNP, CRNP, and Lisa Ray, MS, ELD. The new Birmingham practice, named \"Innovative Fertility Specialists, an INVO Center\" will provide fertility treatment utilizing the efficient, effective, and affordable INVOcell option. The practice has begun seeing patients and expects to perform initial treatment cycles in September 2021. Signed a joint venture agreement with Bloom Fertility to open an INVO Center in Atlanta, Georgia. Led by reproductive specialist Dr. Sue Ellen Carpenter, M.D., the center is scheduled to open in September 2021. Completed the site build-out and preparing to open the Company's INVO Center JV in Monterrey, Mexico, Positib Fertility, with Drs. Francisco Arredondo and Ramiro Ramirez. Expected to open in the October timeframe. Signed a partnership agreement with Lyfe Medical, LLC to establish and operate a clinic in the San Francisco Bay area to offer the INVO procedure. Lyfe Medical will own the clinic while INVO will set-up and manage an embryology center to provide laboratory services to the clinic and its patients in exchange for a share of the clinic's revenue. Expanded capabilities within the global OB/GYN vertical with the appointment of Barbara Levy, M.D., FACOG, FACS as the SVP, global clinical integration. Dr. Levy is considered one of the most influential reproductive health clinical executives in the world, recently serving as Vice President, Health Policy at the American College of Obstetricians and Gynecologists (ACOG) and chair of the American Medical Association/Specialty Society Relative Value Scale Update Committee. Appointed Andrea Goren as CFO, replacing the Company's past utilization of an outside CFO consulti...